Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous infusion versus intermittent bolus beta-lactam antibiotics for severe sepsis
ACTRN12610000238077Phase 2Completed
- Sponsor
- Beta-Lactam Infusion Group
- Start
- Apr 2010
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ticarcillin plus clavulanic acid, piperacillin + tazobactam and meropenem in sepsis (2 arms), sponsored by Beta-Lactam Infusion Group. Primary endpoint: Plasma antibiotic concentration above the minimum inhibitory concentration for three samples. Started Apr 2010; status: completed.
02
Drugs
ticarcillin plus clavulanic acidpiperacillin + tazobactammeropenem
03
Conditions
sepsis
Beyond the preview
Go deeper on ACTRN12610000238077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000238077.